What exactly changed in the PRVA analyst rating on February 26, 2026?

On February 26, 2026 Jefferies maintained a **Buy** and raised its price target to **$32**. Piper Sandler maintained **Overweight** and raised its price target to **$36**. Both were maintenance actions with higher targets, not upgrades or downgrades.

How should investors interpret maintained Buy and Overweight calls in the PRVA analyst rating?

Maintained Buy/Overweight with higher targets suggests analysts expect upside but saw no new material downside. Investors should treat these as positive signals, but compare targets to current price and guidance before trading.

Does the PRVA analyst rating change affect Meyka AI’s grade for PRVA?

Meyka AI rates PRVA with a grade of **B+**. The maintained analyst calls and higher price targets are one input among benchmarks, sector performance, and financial metrics in our grade calculation.

Where can I read the analyst reports mentioned in the PRVA analyst rating update?

The Jefferies and Piper Sandler notes were posted on StreetInsider on February 26, 2026. See the Jefferies note and the Piper Sandler note for full detail. [Jefferies note](https://www.streetinsider.com/Analyst+Comments/Privia+Health+Group+Inc+%28PRVA%29+PT+Raised+to+%2432+at+Jefferies/26069644.html

Analyst Ratings

Jefferies Maintains Buy on PRVA Privia Health Group, Inc. Feb 2026

ByDanny Kontos March 2, 2026

PRVA analyst rating: Jefferies maintained a Buy on PRVA (Privia Health Group, Inc.) on February 26, 2026, and raised its price target to $32. The same day Piper Sandler maintained an Overweight and lifted its target to $36. Both moves were recorded on February 26, 2026 and left the firms’ positive stances intact. Investors should note these are maintained endorsements with higher price targets, not fresh upgrades or downgrades. We highlight the analyst views, price targets, coverage history, and investor implications using Meyka AI’s real-time market analysis.